Helen Zhang

Oversight and lead Roche Pharma China financial business partnering, FP&A, performance management and the Finance operations team including statutory accounting, credit, internal control and other operational matters

Oversight overall corporate & strategic finance including group accounting reporting, FP&A, Tax, Treasury, and global subsidiaries for IMAB group. Core member to complete IMAB’s spin off of its China operations from listed company in NASDAQ and serve as key transition in charge for all financial matters.

Head of Business Finance for integrated GSK China Vaccine business post Novartis Vaccine acquisition; China Vaccine Leadership Team member Finance lead for China strategy, BD and pipelines/Oncology BU;

Head of Business Finance for integrated GSK China Vaccine business post Novartis Vaccine acquisition; China Vaccine Leadership Team member

Rotation Role in SSC in charge of Record to Report and Treasury across China/HK 10 entities, total team size 24 ppl.

Lead Novartis integration project for China Vaccine

Finance Business Partner to Oncology TA; Finance BP for Pricing analysis across all TAs; Finance project lead for Trade model analysis and evaluation; Other finance project management;

Performance management, financial reporting, budgeting&forecasting; APAC regional project lead for BD contract financial review; Plant establishment project controller, project planning and evaluation; Finance training faculty for UCB Pharma Great China;

Management reporting, business review preparation; Operation expenses and supply chain planning

Financial planning for LPG China PU, full P&L responsibility

3 years of management training program in three rotations including tax, financial planning & analysis and GL/SAP implementation. Wide exposure with BP China and internationl finance community, graduated from the program with a high profile.